Kadcyla is primarily used for the treatment of HER2-positive breast cancer. It is approved for use in patients with metastatic breast cancer who have previously been treated with trastuzumab and a taxane, either separately or in combination. Additionally, it is approved as an adjuvant treatment for patients with HER2-positive early breast cancer who have residual invasive disease after receiving neoadjuvant therapy that includes trastuzumab and chemotherapy.
